ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary

ADC Therapeutics SA

08/08/2023 13:38

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 58 cents​​ per share for the quarter ended in June. The mean
expectation of eight analysts for the quarter was for a loss
of 46 cents per share.
    * Revenue rose 11.5% to $19.28 million from a year ago;
analysts
expected $41.56 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 58 cents​.
    * The mean earnings estimate of analysts had risen by
about 21.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * ADC Therapeutics SA shares had fallen by 33.5% this
quarter and
lost 62.8% so far this year.
    * The company reported a quarterly loss of $47.12 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $8.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 12:37 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.46          -0.58          Missed
 Mar. 31 2023      -0.67          -0.74          Missed
 Dec. 31 2022      -0.29          -0.30          Missed
 Sep. 30 2022      -0.35          -0.65          Missed